CWChamarika Jayanetti Weerasekera

Chamarika Jayanetti Weerasekera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chamarika Jayanetti Weerasekera has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cerebral malaria: of mice and men

    by Chamarika J Weerasekera, Nicholas J White

    Background: Cerebral malaria is a major cause of death in endemic areas. An animal model of cerebral malaria has been studied widely in which C57BL/6 mice are infected with the Plasmodium berghei ANKA strain. The histopathology and the response to interventions of human cerebral malaria and the murine model are very different. In 2012, a consensus guideline was published recommending that in order to represent better the clinical setting, interventions in the murine model should be tested together with antimalarial drug treatment and after development of the cerebral syndrome. Methods: A systematic review of publications on human and murine cerebral malaria since 2010 was conducted. Results: Clinical research on human cerebral malaria has declined and still no adjuvant intervention has proved effective. Meanwhile, since 2010, 149 interventions (118 adjuvants) have been evaluated in the mouse model, of which 142 (95%) were reportedly successful. Only 26% of interventions were evaluated after the development of the murine cerebral syndrome and 65% of the adjuvants were tested without a concomitant antimalarial. Conclusion: The predictive value of the murine model in identifying adjuvant therapeutic interventions in human cerebral malaria is very poor.


  • Open Access

    Ivermectin- a necessity for the control of neglected tropical diseases in Sri Lanka

    by Chamarika Jayanetti Weerasekera, Shalindra Ranasinghe, Kosala Gayan Weerakoon, Nilanthi Renuka de Silva

    Ivermectin, a broad spectrum anti-parasitic agent, has been recognised by the World Health Organization as an essential medicine for decades. It has never been registered for human use in Sri Lanka. This review aims to discuss the usefulness of ivermectin with regards to locally endemic neglected tropical diseases, namely, strongyloidiasis, trichuriasis, lymphatic filariasis and scabies.

  • Strongyloidiasis in end-stage renal disease in Sri Lanka: urging research, improved diagnostics and access to ivermectin

    by Chamarika Jayanetti Weerasekera, Nayana Gunathilaka, Nilanka Perera, Nilanthi Renuka de Silva, Renu Wickremasinghe

  • Open Access

    Concurrent Toxoplasmosis in a Patient with Hodgkin Lymphoma: A Case Report

    by Y. K. Perera, C. J. Weerasekera, M. A. D. P. K. Wijesinghe, M. P. K. Gamage, W. K. Mahesh, M. M. I. R. Silva, S. M. Muthukumarana, M. S. V. B. Pinto, M. Somathilaka, S. P. Gunasekara

    A 14-year-old previously healthy boy was investigated for unilateral cervical lymphadenopathy. The biopsy of the posterior cervical lymph node was suggestive of toxoplasmosis. Polymerase chain reaction on blood for Toxoplasma gondii was also positive, however, his serology was negative for T. gondii-specific antibodies. A repeat cervical lymph node biopsy performed in a different hospital revealed classic Hodgkin lymphoma with co-existent toxoplasmosis thus the child was transferred to the National Cancer Institute, Sri Lanka for further management. He was started on anticancer chemotherapy as well as pyrimethamine-sulfadiazine and folinic acid for toxoplasmosis. As the child was intolerant to the pyrimethamine-sulfadiazine combination, he was started on co-trimoxazole and is on further follow-up. This case reiterates the importance of promptly ruling out sinister diagnoses such as malignancies when presenting with lymphadenopathy, and the need for concurrent management of co-existent, opportunistic infections that would impair the clinical outcome of the immunocompromised host.

  • Open Access

    Detection of human strongyloidiasis among patients with a high risk of complications attending selected tertiary care hospitals in Colombo, Sri Lanka using molecular and serological diagnostic tools

    by Chamarika Jayanetti Weerasekera, Nayana Gunathilaka, Chandrani Menike, Philip Anpahalan, Nilanka Perera, Nilanthi Renuka de Silva, Renu Wickremasinghe

    Background: Strongyloidiasis a neglected tropical disease is known to cause severe disease among immunosuppressed and has not been studied extensively in Sri Lanka. Parasitological diagnostic approaches based on faecal microscopy and culture often fail to detect low-intensity infections. This study investigates the presence of strongyloidiasis among selected immunocompromised individuals using parasitological, molecular and serological techniques. Methods: Adult patients with immunocompromising conditions admitted to three tertiary care hospitals in Sri Lanka were recruited. A faecal sample and 2 ml of venous blood were collected. The faecal samples were subjected to direct faecal smear and cultures (agar plate, charcoal and Harada-Mori) and polymerase chain reaction (PCR) using species specific primers designed for Strongyloides stercoralis. The presence of Strongyloides IgG antibodies was tested in the collected serum samples using DRG Strongyloides IgG enzyme-linked immunosorbent assay (ELISA) kits. The PCR products of the positive samples were sequenced using Sanger sequencing method. Results: A total of 260 patients were recruited to this study, out of which 160 provided faecal samples and 122 provided blood samples. Out of the 160 faecal samples, none were positive for strongyloidiasis by direct smear, charcoal and Harada-Mori cultures. Only one sample (0.6%) was positive by agar plate culture. Out of the 123 samples subjected to PCR, 14 (11.4%), including the culture positive patient, were positive for S. stercoralis. Sequencing results of the PCR products indicated 100% similarity to S. stercoralis. Out of the 122 serum samples subjected to ELISA, 20 (16.4%), including the culture positive patient, were positive for Strongyloides IgG antibodies. However, sociodemographic, exposure factors, clinical features were not significantly associated with the presence of strongyloidiasis infection. Conclusions: Strongyloidiasis is present among the immunocompromised population in Sri Lanka, even in the absence of a significant relationship with associated factors. It is advisable to screen such patients with highly sensitive tests such as PCR for early diagnosis and treatment. Graphical


  • Open Access

    Incidental diagnosis of strongyloidiasis in a patient with hepatic metastasis

    by C. J. Weerasekera, C. W. Menike, J. P. Anpahalan, S. A. A. Senevirathne, N. Perera, N. R. De Silva, D. R. Wickremasinghe

    Strongyloides stercoralis is a soil-transmitted helminth infecting humans that can cause hyperinfection and disseminated disease in the immunocompromised host. This case report describes a 56-year-old patient, diagnosed with hepatic metastasis, who was screened for strongyloidiasis by faecal culture. The agar plate culture became positive on the third day of incubation, demonstrating characteristic tracks and yielding rhabditiform larvae. The charcoal and Harada-Mori cultures were negative. The patient was treated with albendazole for 7 days but declined further follow up.

  • Open Access

    Omental dirofilariasis caused by Dirofilaria repens; visceralisation in a patient with diabetes mellitus

    by C. J. Weerasekera, C. Hapuachchige, Y. M. T. Y. Wijeratne, R. Goonesinghe, D. R. Wickremasinghe, T. C. Yahathugoda, S. Ranasinghe


  • Case Report: The First Case of Genotypically Confirmed Plasmodium falciparum Kelch 13 Propeller Mutation in Sri Lanka and Its Implications on the Elimination Status of Malaria

    by Deepika Fernando, Chamarika Jayanetti Weerasekera, W. M. Kumudunayana T. de A. W. Gunasekera, H. Chanditha Hapuarachchi, Carmen Koo, Muzrif Munas, Prasad Ranaweera

    This case report discusses recrudescence of imported Plasmodium falciparum malaria, in the presence of P. falciparum Kelch13 (PfK13) propeller mutation, in a patient diagnosed and fully treated with artemether–lumefantrine under direct observation in Sri Lanka. This patient presented with a history of 5 days of fever following his arrival from the Democratic Republic of Congo (DRC). He had visited Rwanda 1 week before arrival to Sri Lanka. Treatment was commenced with artemisinin-based combination therapy, artemether–lumefantrine, which is the first-line drug recommended for uncomplicated falciparum malaria. Blood smears were negative for parasites by the third day of treatment. Approximately 2 weeks later, he developed fever again and was diagnosed as having a recrudescence of falciparum malaria. He was treated and responded to the second-line antimalarial dihydroartemisinin–piperaquine. Molecular testing of blood taken from the first infection revealed the presence of amino acid substitutions K189T and R561H within the PfK13 gene. R561H mutation is associated with delayed parasite clearance in Southeast Asia. Although seldom reported from DRC, an emergence and clonal expansion of parasites harboring R561H allele has been reported from Rwanda recently; thus, it is likely that this patient may have got the infection from Rwanda. Sri Lanka eliminated malaria in 2016. However, in the backdrop of continuing imported malaria cases, early diagnosis and prompt treatment is essential to prevent the re-establishment of the disease.